About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify
16 December 2019
Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer
10 February 2020
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Published by
Julie Ficheux
on
7 January 2020
No translations available for this page
